Cambrex Gets FDA Warning on Milan API Facility

Cambrex (East Rutherford, NJ) says it has received a warning letter from the U.S. FDA, relating to the collection and maintenance of certain laboratory data at the company’s generic active pharmaceutical ingredients (API) manufacturing facility at Milan, Italy. The warning letter follows an FDA inspection of the Milan facility in March 2009. The warning letter indicated that until Cambrex corrects all the observations, the FDA may withhold approval of new applications or supplements listing the Milan facility as the API manufacturer, and products...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers